Nalaganje...
Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Lymphoproliferative Disorders
INTRODUCTION: Chemoimmunotherapeutic regimens using the anti-CD20 antibody rituximab improved significantly the survival rates in various B-cell lymphoproliferative disorders (LPDs), including chronic lymphocytic leukemia (CLL). The next-generation CD20 antibody obinutuzumab represents an addition t...
Shranjeno v:
| izdano v: | Expert Opin Biol Ther |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6166403/ https://ncbi.nlm.nih.gov/pubmed/28893099 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14712598.2017.1377178 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|